EUVIMEDEUVIMED entdecken
Crossref

Population Pharmacokinetic and Pharmacodynamic Model of Propofol in Patients With Chronic Kidney Disease

Rachna Rohilla iD, Jaya Shree Dilli Batcha, Preethy Mathew iD, Goverdhan Dutt Puri, Surulivelrajan Mallayasamy iD, Ravimohan S Mavuduru, Arup Kumar Mandal, Smita Pattanaik iD

The Journal of Clinical Pharmacology · 2026-11 · 66 (11)

DOI: 10.1002/jcph.70268 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 01.11.2026. Verfasst von Rachna Rohilla und 7 weiteren Autor:innen. Beteiligte Einrichtung: Assistant Professor, Department of Pharmacology, All India Institute of Medical Sciences, Bathinda, Punjab, India. Hauptthemen laut MEDLINE: Propofol, Anesthetics, Intravenous, Renal Insufficiency, Chronic, Models, Biological. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Postgraduate Institute of Medical Education and Research, Chandigarh, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Propofol is a commonly used intravenous anesthetic. Although the kidney plays a minor role in elimination, pharmacokinetics (PK) and pharmacodynamics (PD) have been found to be significantly affected in patients with chronic kidney disease (CKD). The study was a prospective, single‐centre study in CKD patients undergoing surgery under general anaesthesia. A total of 9–10 blood samples were collected from each of 38 patients at prespecified sampling time points for propofol quantification. Time to loss of consciousness and time to eye opening were recorded, along with the bispectral index (BIS), as PD endpoints. The concentration time profile (287 samples) and BIS data from 35 patients were included in model development. Creatinine clearance was identified as an important covariate affecting the PK model. Stage 3 and 4 patients achieved higher plasma concentrations at the same induction and maintenance propofol doses and tended to have lower BIS. The propofol C max was higher in stage 4 patients than in stages 1 or 2. The average concentration at LOC was significantly higher in stage 4 (6.61 ± 6.28 µg/mL) as compared to stages 1 (2.06 ± 1.69 µg/mL) or stage 2 (1.64 ± 1.77 µg/mL). Average time to eye opening was also higher in stages 3 and 4 (12.9 ± 4.7 and 9.5 ± 3.1 min, respectively) as compared to stages 1 and 2 (7 ± 3.2 and 7.9 ± 2.4 min, respectively). The moderate‐severe renal impairment status decreases the requirement of the induction dose of propofol to achieve surgical anesthesia compared to those with normal creatinine clearance. Prolonged clearance also leads to prolonged emergence from anesthesia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PropofolAnesthetics, IntravenousRenal Insufficiency, ChronicModels, BiologicalHumansFemaleMaleMiddle AgedProspective StudiesAgedAdultCreatinineAnesthesia, General

Stichwörter der Autor:innen

PK‐PD modelchronic kidney diseasepharmacodynamicspharmacokineticspropofolrenal failure

Substanzen

PropofolAnesthetics, IntravenousCreatinine

Autor:innen und Institutionen

  • Assistant Professor, Department of Pharmacology, All India Institute of Medical Sciences, Bathinda, Punjab, India.
  • Research Scholar, Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, India.
  • Professor, Department of Anaesthesia and Intensive Care, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Professor of Anaesthesia and Executive Director, All India Institute of Medical Sciences, Jodhpur, India.
  • Professor Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, India.
  • Professor, Department of Urology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.

ORCID-Profile: Rachna Rohilla, Preethy Mathew, Surulivelrajan Mallayasamy, Smita Pattanaik

Förderung

  • Postgraduate Institute of Medical Education and Research, Chandigarh, India

Zitieren

APA

Rohilla, R., Batcha, J. S. D., Mathew, P., Puri, G. D., Mallayasamy, S., Mavuduru, R. S., Mandal, A. K., & Pattanaik, S. (2026). Population Pharmacokinetic and Pharmacodynamic Model of Propofol in Patients With Chronic Kidney Disease. The Journal of Clinical Pharmacology, 66(11). https://doi.org/10.1002/jcph.70268

Vancouver

Rohilla R, Batcha JSD, Mathew P, Puri GD, Mallayasamy S, Mavuduru RS, et al. Population Pharmacokinetic and Pharmacodynamic Model of Propofol in Patients With Chronic Kidney Disease. The Journal of Clinical Pharmacology. 2026;66(11). doi:10.1002/jcph.70268

BibTeX
@article{Rohilla2026,
  author = {Rohilla, Rachna and Batcha, Jaya Shree Dilli and Mathew, Preethy and Puri, Goverdhan Dutt and Mallayasamy, Surulivelrajan and Mavuduru, Ravimohan S and Mandal, Arup Kumar and Pattanaik, Smita},
  title = {Population Pharmacokinetic and Pharmacodynamic Model of Propofol in Patients With Chronic Kidney Disease},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  volume = {66},
  number = {11},
  doi = {10.1002/jcph.70268}
}
Kostenlos starten →